EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of…
Posted: December 9, 2021 at 1:42 am
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca's EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorization (EUA) in the US for the pre-exposure prophylaxis (prevention) of COVID-19, with first doses expected to become available very soon.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208006139/en/
(Photo: Business Wire)
The Food and Drug Administration (FDA) granted the EUA for EVUSHELD for pre-exposure prophylaxis of COVID-19 in adults and adolescents (aged 12 and older who weigh 40kg or more) with moderate to severe immune compromise due to a medical condition or immunosuppressive medications and who may not mount an adequate immune response to COVID-19 vaccination, as well as those individuals for whom COVID-19 vaccination is not recommended. Recipients should not be currently infected with or had recent known exposure to a person infected with SARS-CoV-2.
Myron J. Levin, MD, Professor of Pediatrics and Medicine, University of Colorado School of Medicine, US, and principal investigator on the PROVENT trial, said: Millions of people in the US and around the world remain at serious risk for COVID-19 because their immune systems do not generate a sufficient immune response, even after receiving all recommended doses of vaccine. I am excited to offer my patients EVUSHELD as an easily-administered new option that provides long-lasting protection that could help them return to their everyday lives.
Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: We are proud to play a leading role in fighting the COVID-19 pandemic and, with EVUSHELD, we now have the first antibody therapy authorized in the US to prevent COVID-19 symptoms before virus exposure, while also providing long lasting protection with a single dose. EVUSHELD neutralizes all previous SARS-CoV-2 variants to date, and we are working quickly to establish its efficacy against the new Omicron variant. We thank our clinical trial participants, the investigators, scientists, and government agencies and our colleagues at AstraZeneca who have all contributed to the development of EVUSHELD.
Brian Koffman, MDCM (retired), MS Ed, Co-Founder, Executive Vice President and Chief Medical Officer of the CLL (Chronic Lymphocytic Leukemia) Society, US, said: One of the primary questions I keep getting asked by patients is When can I hug my grandchildren again? As a physician and person with a weakened immune system, l am filled with hope now that EVUSHELD will soon be available to those who cant count on vaccination alone to provide the protection they need.
EVUSHELD is a combination of two long-acting monoclonal antibodies and is the only antibody therapy authorized in the US for COVID-19 pre-exposure prophylaxis and the only COVID-19 antibody delivered as an intramuscular dose (150mg tixagevimab and 150mg cilgavimab).
About 2% of the global population is considered at increased risk of an inadequate response to a COVID-19 vaccine.1,2 About seven million people in the US are immunocompromised and may benefit from EVUSHELD for pre-exposure prophylaxis of COVID-19.1,3,4 This includes people with blood cancers or other cancers being treated with chemotherapy, and those taking medications after an organ transplant or who are taking immunosuppressive drugs for conditions including multiple sclerosis and rheumatoid arthritis.5-9
The primary data supporting the EVUSHELD EUA are from the ongoing PROVENT Phase III pre-exposure prevention trial, which showed a statistically significant reduction (77% at primary analysis, 83% at median six-month analysis) in the risk of developing symptomatic COVID-19 compared to placebo, with protection from the virus continuing for at least six months. More follow-up is needed to establish the full duration of protection provided by EVUSHELD. Data from the Phase III STORM CHASER post-exposure trial and the EVUSHELD Phase I trial also supported the EUA. EVUSHELD was well-tolerated in the trials.
EVUSHELD and SARS-CoV-2 variants
Studies are underway to provide information on the impact of the new Omicron variant (B.1.1.529) on EVUSHELD.10,11 Of the Omicron binding site substitutions relevant to EVUSHELD that have been tested to date in preclinical assays, none have been associated with escape from EVUSHELD neutralization.10,11 In vitro findings demonstrate EVUSHELD neutralizes other recent emergent SARS-CoV-2 viral variants, including the Delta and Mu variants.10
EVUSHELD is being developed with support from the US government, including federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority in partnership with the Department of Defense; Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, under Contract No. W911QY-21-9-0001.
AstraZeneca has agreed to supply the US government with 700,000 doses of EVUSHELD. The US government has indicated that it plans to distribute these doses to states and territories at no cost and on a pro rata basis.
AstraZeneca is progressing with filings around the globe for potential emergency use authorization or conditional approval of EVUSHELD in both COVID-19 prophylaxis and treatment.
EVUSHELD is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of EVUSHELD under Section 564(b)(1) of the Food, Drug and Cosmetic Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
IMPORTANT SAFETY INFORMATION
EVUSHELD (tixagevimab co-packaged with cilgavimab) has not been approved, but has been granted an Emergency Use Authorization (EUA) by FDA. There are limited clinical data available and serious and unexpected adverse events may occur that have not been previously reported with EVUSHELD use.
Contraindication:
EVUSHELD is contraindicated in individuals with previous severe hypersensitivity reactions, including anaphylaxis, to any component of EVUSHELD.
Warnings and Precautions:
Hypersensitivity Including Anaphylaxis
Serious hypersensitivity reactions, including anaphylaxis, have been observed with IgG1 monoclonal antibodies like EVUSHELD. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive therapy. Clinically monitor individuals after injections and observe for at least 1 hour.
Clinically Significant Bleeding Disorders
As with any other intramuscular injection, EVUSHELD should be given with caution to individuals with thrombocytopenia or any coagulation disorder.
Cardiovascular Events
A higher proportion of subjects who received EVUSHELD versus placebo reported myocardial infarction and cardiac failure serious adverse events. All of the subjects with events had cardiac risk factors and/or a prior history of cardiovascular disease at baseline. A causal relationship between EVUSHELD and these events has not been established. Consider the risks and benefits prior to initiating EVUSHELD in individuals at high risk for cardiovascular events, and advise individuals to seek immediate medical attention if they experience any signs or symptoms suggestive of a cardiovascular event.
Adverse Reactions:
The most common adverse events are headache, fatigue and cough.
Use in Specific Populations:
Pregnancy
There are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. EVUSHELD should only be used during pregnancy if the potential benefit outweighs the potential risk for the mother and the fetus.
Lactation
There are no available data on the presence of tixagevimab or cilgavimab in human milk or animal milk, the effects on the breastfed infant, or the effects of the drug on milk production. Maternal IgG is known to be present in human milk.
Pediatric Use
EVUSHELD is not authorized for use in pediatric individuals under 12 years of age or weighing less than 40 kg. The safety and effectiveness of EVUSHELD have not been established in pediatric individuals.
AUTHORIZED USE
EVUSHELD (tixagevimab co-packaged with cilgavimab) is authorized for use under an EUA for the pre-exposure prophylaxis of COVID-19 in adults and pediatric individuals (12 years of age and older weighing at least 40 kg):
EVUSHELD has been authorized by FDA for the emergency use described above. EVUSHELD is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19.
EVUSHELD is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of EVUSHELD under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
LIMITATIONS OF AUTHORIZED USE
See Full Fact Sheet for Healthcare Providers for examples of medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination, the justification for emergency use of drugs during the COVID-19 pandemic, information on available alternatives, and additional information on COVID-19.
The FDA Letter of Authorization is available for reference, as well as the Fact Sheet for Patients, Parents And Caregivers.
SARS-CoV-2 Viral Variant
There is a potential risk of treatment failure due to the development of viral variants that are resistant to tixagevimab and cilgavimab administered together. Prescribing healthcare providers should consider the prevalence of SARS-CoV-2 variants in their area, where data are available, when considering prophylactic treatment options.
Reporting Adverse Events
The prescribing healthcare provider and/or your designee must report all SERIOUS ADVERSE EVENTS and MEDICATION ERRORS potentially related to EVUSHELD within 7 calendar days from the healthcare providers awareness of the event (1) by submitting FDA Form 3500 online, (2) by downloading FDA Form 3500 and then submitting by mail or fax, or (3) contacting the FDA at 1-800-FDA-1088 to request this form.
In addition, please fax a copy of all FDA MedWatch forms to AstraZeneca at 1-866-742-7984.
Report adverse events by visiting https://contactazmedical.astrazeneca.com, or calling AstraZeneca at 1-800-236-9933.
Notes
EVUSHELD
EVUSHELD, formerly known as AZD7442 is a combination of two LAABs - tixagevimab (AZD8895) and cilgavimab (AZD1061) - derived from B-cells donated by convalescent patients after SARS-CoV-2 virus. Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein13 and were optimized by AstraZeneca with half-life extension and reduced Fc receptor and complement C1q binding. The half-life extension more than triples the durability of its action compared to conventional antibodies and could afford up to 12 months of protection from COVID-19 following a single administration;14-16 data from the Phase III PROVENT trial show protection lasting at least six months.17 The reduced Fc receptor binding aims to minimize the risk of antibody-dependent enhancement of disease - a phenomenon in which virus-specific antibodies promote, rather than inhibit, infection and/or disease.18 EVUSHELD is delivered as an IM dose of 150mg tixagevimab and 150mg cilgavimab administered in two separate, consecutive injections.
In August 2021, AstraZeneca announced that EVUSHELD demonstrated a statistically significant reduction in the risk of developing symptomatic COVID-19 in the PROVENT trial; efficacy was 83% compared to placebo in a six-month analysis announced on November 18, 2021. In October 2021, AstraZeneca announced positive high-level results from the EVUSHELD TACKLE Phase III outpatient treatment trial. EVUSHELD is also being studied as a potential treatment for hospitalized COVID-19 patients as part of the National Institute of Healths ACTIV-3 trial and in an additional collaborator hospitalization treatment trial.
Under the terms of the licensing agreement with Vanderbilt, AstraZeneca will pay single-digit royalties on future net sales.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. For more information, please visit http://www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.
References
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208006139/en/
See the rest here:
EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of...
- Life Extension Information, Research and Products [Last Updated On: May 4th, 2015] [Originally Added On: May 4th, 2015]
- Life extension - Wikipedia, the free encyclopedia [Last Updated On: May 4th, 2015] [Originally Added On: May 4th, 2015]
- Forever Young - Short Documentary (Regenerative Medicine/Life Extension) - Video [Last Updated On: May 4th, 2015] [Originally Added On: May 4th, 2015]
- An argument with a life extension denier - Video [Last Updated On: May 4th, 2015] [Originally Added On: May 4th, 2015]
- Life extension deniers part 3: their ignorance and stupidity - Video [Last Updated On: May 4th, 2015] [Originally Added On: May 4th, 2015]
- Life extension science, also known as anti-aging medicine, - Video [Last Updated On: May 4th, 2015] [Originally Added On: May 4th, 2015]
- NEWS - Life Extension [Last Updated On: May 22nd, 2015] [Originally Added On: May 22nd, 2015]
- Life Extension Vitamins | Health Supplements | Garcinia ... [Last Updated On: May 22nd, 2015] [Originally Added On: May 22nd, 2015]
- The Life Extension Blog [Last Updated On: July 14th, 2015] [Originally Added On: July 14th, 2015]
- About Life Extension: Anti-Aging, Health Supplements ... [Last Updated On: August 7th, 2015] [Originally Added On: August 7th, 2015]
- Life Extension - Products on Sale, Coupons, Reviews, Free ... [Last Updated On: August 22nd, 2015] [Originally Added On: August 22nd, 2015]
- Life Extension - Reviews - eVitamins.com [Last Updated On: September 2nd, 2015] [Originally Added On: September 2nd, 2015]
- Life Extension Manual - A Guide to Anti-aging, Genomes, and ... [Last Updated On: September 2nd, 2015] [Originally Added On: September 2nd, 2015]
- Vitamins & Supplements | Life Extension Europe [Last Updated On: September 2nd, 2015] [Originally Added On: September 2nd, 2015]
- Life Extension News - Life Enhancement Products [Last Updated On: September 2nd, 2015] [Originally Added On: September 2nd, 2015]
- Life Extension diet & fitness | drugstore.com [Last Updated On: September 2nd, 2015] [Originally Added On: September 2nd, 2015]
- Life Extension: Durk Pearson, Sandy Shaw: 9780446512299 ... [Last Updated On: September 3rd, 2015] [Originally Added On: September 3rd, 2015]
- Life Extension [Last Updated On: September 9th, 2015] [Originally Added On: September 9th, 2015]
- The Las Vegas A4M Conference - Life Extension [Last Updated On: September 22nd, 2015] [Originally Added On: September 22nd, 2015]
- Life Extension Technology and Tissue Regeneration [Last Updated On: October 25th, 2015] [Originally Added On: October 25th, 2015]
- Ann Arbor Life Extension [Last Updated On: October 28th, 2015] [Originally Added On: October 28th, 2015]
- Life Extension Supplements/Products: Antioxidants, Anti ... [Last Updated On: November 4th, 2015] [Originally Added On: November 4th, 2015]
- About Us - Life Extension [Last Updated On: January 27th, 2016] [Originally Added On: January 27th, 2016]
- Most Popular - Life Extension Vitamins [Last Updated On: February 12th, 2016] [Originally Added On: February 12th, 2016]
- Alcor Procedures - Alcor Life Extension Foundation [Last Updated On: February 14th, 2016] [Originally Added On: February 14th, 2016]
- Alcor Life Extension Foundation - Wikipedia, the free ... [Last Updated On: February 19th, 2016] [Originally Added On: February 19th, 2016]
- New... - Life Extension Vitamins [Last Updated On: June 30th, 2016] [Originally Added On: June 30th, 2016]
- Life Extension Mix Tablets, 315 tablets [Last Updated On: July 8th, 2016] [Originally Added On: July 8th, 2016]
- Directory of Innovative Anti-Aging Doctors, Health And ... [Last Updated On: July 18th, 2016] [Originally Added On: July 18th, 2016]
- Hormone / Prostate - Life Extension Vitamins [Last Updated On: July 26th, 2016] [Originally Added On: July 26th, 2016]
- Life Extension - Page 1 - Health Food Emporium [Last Updated On: September 24th, 2016] [Originally Added On: September 24th, 2016]
- Life Extension Super Bio-Curcumin -- 400 mg - 60 ... - Vitacost [Last Updated On: October 18th, 2016] [Originally Added On: October 18th, 2016]
- Life extension - Wikipedia [Last Updated On: October 25th, 2016] [Originally Added On: October 25th, 2016]
- Heart / Circulation - Life Extension Vitamins [Last Updated On: December 2nd, 2016] [Originally Added On: December 2nd, 2016]
- Life Extension - iHerb.com [Last Updated On: January 19th, 2017] [Originally Added On: January 19th, 2017]
- Orbital ATK files suit against DARPA - Inside Defense (subscription) [Last Updated On: February 8th, 2017] [Originally Added On: February 8th, 2017]
- Biotechnology xpert Jamie Metzl addresses realities of genetics revolution, Feb. 9 - Vail Daily News [Last Updated On: February 8th, 2017] [Originally Added On: February 8th, 2017]
- There is No Limit to Human Life Extension - Futurism [Last Updated On: February 8th, 2017] [Originally Added On: February 8th, 2017]
- Human Life Could Be Extended Indefinitely, Study Suggests - EconoTimes [Last Updated On: February 10th, 2017] [Originally Added On: February 10th, 2017]
- DARPA hits snag in GEO satellite service plan - Network World [Last Updated On: February 10th, 2017] [Originally Added On: February 10th, 2017]
- Orbital ATK Sues DARPA Over Satellite-Repairing Robots | Inverse - Inverse [Last Updated On: February 13th, 2017] [Originally Added On: February 13th, 2017]
- Radical Life Extension Is Already Here, But We're Doing it ... [Last Updated On: February 13th, 2017] [Originally Added On: February 13th, 2017]
- Private Space Company Suing US Gov't For Stealing Their Idea ... - Daily Caller [Last Updated On: February 15th, 2017] [Originally Added On: February 15th, 2017]
- SRS's Melter 2 to be replaced | News | northaugustastar.com - The Star [Last Updated On: February 15th, 2017] [Originally Added On: February 15th, 2017]
- Acacia Mining sees 40 percent boost from mine extension | Reuters - Reuters [Last Updated On: February 15th, 2017] [Originally Added On: February 15th, 2017]
- Double-blind, randomized crossover study of intravenous infusion of ... - PR Newswire (press release) [Last Updated On: February 15th, 2017] [Originally Added On: February 15th, 2017]
- Only Human - New Republic [Last Updated On: February 17th, 2017] [Originally Added On: February 17th, 2017]
- Batteroo Boost, The Battery Life Extender Is Now Available Worldwide - PR Newswire (press release) [Last Updated On: February 17th, 2017] [Originally Added On: February 17th, 2017]
- Why Do People Want to Live So Long, Anyway? - TIME [Last Updated On: February 17th, 2017] [Originally Added On: February 17th, 2017]
- Major South African coal extension project on cards South32 - Creamer Media's Mining Weekly [Last Updated On: February 17th, 2017] [Originally Added On: February 17th, 2017]
- Evolution approves Cowal life extension project - Creamer Media's Mining Weekly [Last Updated On: February 17th, 2017] [Originally Added On: February 17th, 2017]
- Should We Die? - The Atlantic [Last Updated On: February 18th, 2017] [Originally Added On: February 18th, 2017]
- When Screening for Disease, Risk is as Important to Consider as ... - University of Virginia [Last Updated On: February 20th, 2017] [Originally Added On: February 20th, 2017]
- A UO lab digs into worms in the quest to lengthen human life - AroundtheO [Last Updated On: February 21st, 2017] [Originally Added On: February 21st, 2017]
- Life Extension Science Live Forever and Don't Pay Taxes - Nanalyze [Last Updated On: February 23rd, 2017] [Originally Added On: February 23rd, 2017]
- Who wants to live forever? Transhumanism's promise of eternal life - Irish Times [Last Updated On: March 18th, 2017] [Originally Added On: March 18th, 2017]
- Editorial March 29 2017 - Illawarra Mercury [Last Updated On: March 28th, 2017] [Originally Added On: March 28th, 2017]
- Life Extension and Insilico Medicine Use Artificial Intelligence to Develop Ageless Cell - WholeFoods Magazine [Last Updated On: March 28th, 2017] [Originally Added On: March 28th, 2017]
- Texas A&M Agri-Life Extension Invites Resident to Partake in - RGVProud [Last Updated On: March 28th, 2017] [Originally Added On: March 28th, 2017]
- Life Extension and Insilico Medicine Use Artificial Intelligence to Develop Ageless - WholeFoods Magazine [Last Updated On: March 31st, 2017] [Originally Added On: March 31st, 2017]
- How does where you live affect your life expectancy? | PBS NewsHour - PBS NewsHour [Last Updated On: May 12th, 2017] [Originally Added On: May 12th, 2017]
- Possible mine-life extension good news for contractors - Otago Daily Times [Last Updated On: July 1st, 2017] [Originally Added On: July 1st, 2017]
- SES and MDA Announce First Satellite Life Extension Agreement - Space Daily [Last Updated On: July 1st, 2017] [Originally Added On: July 1st, 2017]
- GARDENING: Reviving St. Augustine grass - Odessa American [Last Updated On: July 3rd, 2017] [Originally Added On: July 3rd, 2017]
- Does doxycycline treat h pylori ulcers - Shelf life extension program doxycycline - Longboat Key News [Last Updated On: July 6th, 2017] [Originally Added On: July 6th, 2017]
- This Study Could Help Extend the Human Lifespan - Futurism [Last Updated On: July 8th, 2017] [Originally Added On: July 8th, 2017]
- A surgeon aiming to do the first human head transplant says 'Frankenstein' predicted a crucial part of the surgery - South China Morning Post [Last Updated On: July 10th, 2017] [Originally Added On: July 10th, 2017]
- Silicon Valley looking to extend life | News, Sports, Jobs - The ... - Tiffin Advertiser Tribune [Last Updated On: July 31st, 2017] [Originally Added On: July 31st, 2017]
- TransCanada still sees producer support for Keystone XL - WorldOil (subscription) [Last Updated On: July 31st, 2017] [Originally Added On: July 31st, 2017]
- US approves $115m sale of F/A-18 Super Hornet upgrades to Switzerland - Airforce Technology [Last Updated On: August 1st, 2017] [Originally Added On: August 1st, 2017]
- BAE Systems sales fire up as tank orders roll in - shropshirestar.com [Last Updated On: August 2nd, 2017] [Originally Added On: August 2nd, 2017]
- New ICBM Cheaper Than Upgraded Minuteman: Boeing On GBSD - Breaking Defense [Last Updated On: August 3rd, 2017] [Originally Added On: August 3rd, 2017]
- BWXT Nuclear Energy Canada Awarded CA$34 Million Contract for Primary Heat Transport Motors - Business Wire (press release) [Last Updated On: August 3rd, 2017] [Originally Added On: August 3rd, 2017]
- BWXT Nuclear Energy Canada in Peterborough lands five-year, $34M deal to make primary heat transport motors for ... - Peterborough Examiner [Last Updated On: August 3rd, 2017] [Originally Added On: August 3rd, 2017]
- FAA Issues Structural Life Extension for Eclipse Jets | Business ... - Aviation International News [Last Updated On: August 3rd, 2017] [Originally Added On: August 3rd, 2017]
- BWXT NEC to provide seven heat transport motors for Bruce Power reactors - Power Technology [Last Updated On: August 4th, 2017] [Originally Added On: August 4th, 2017]
- Johanna and Mario Host Extension Leadership Workshop - KSST (press release) (registration) (blog) [Last Updated On: August 4th, 2017] [Originally Added On: August 4th, 2017]
- Can you take medications past their expiration date? - CBS News [Last Updated On: August 4th, 2017] [Originally Added On: August 4th, 2017]
- Ted Williams will be first baseball player to get 'American Masters' treatment - The Boston Globe [Last Updated On: August 4th, 2017] [Originally Added On: August 4th, 2017]
- Which Giant Tech Company Is Winning the Race to Be Skynet? - Vulture [Last Updated On: August 5th, 2017] [Originally Added On: August 5th, 2017]